RT Journal Article
SR Electronic
T1 Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.11.20151324
DO 10.1101/2020.07.11.20151324
A1 Emelie Marklund
A1 Susannah Leach
A1 Hannes Axelsson
A1 Kristina Nyström
A1 Heléne Norder
A1 Mats Bemark
A1 Davide Angeletti
A1 Anna Lundgren
A1 Staffan Nilsson
A1 Lars-Magnus Andersson
A1 Aylin Yilmaz
A1 Magnus Lindh
A1 Jan-Åke Liljeqvist
A1 Magnus Gisslén
YR 2020
UL http://medrxiv.org/content/early/2020/07/11/2020.07.11.20151324.abstract
AB Background To accurately interpret COVID-19 seroprevalence surveys, knowledge of serum-IgG responses to SARS-CoV-2 with a better understanding of patients who do not seroconvert, is imperative. This study aimed to describe serum-IgG responses to SARS-CoV-2 in a cohort of patients with both severe and mild COVID-19, including extended studies of patients who remained seronegative more than 90 days post symptom onset.Results Forty-seven patients (mean age 49 years, 38% female) were included. All (15/15) patients with severe symptoms and 29/32 (90.6%) patients with mild symptoms of COVID-19 developed SARS-CoV-2-specific IgG antibodies in serum. Time to seroconversion was significantly shorter (median 11 vs. 22 days, P=0.04) in patients with severe compared to mild symptoms. Of the three patients without detectable IgG-responses after >90 days, all had detectable virus-neutralizing antibodies and in two, spike-protein receptor binding domain-specific IgG was detected with an in-house assay. Antibody titers were preserved during follow-up and all patients who seroconverted, irrespective of the severity of symptoms, still had detectable IgG levels >75 days post symptom onset.Conclusions Patients with severe COVID-19 both seroconvert earlier and develop higher concentrations of SARS-CoV-2-specific IgG than patients with mild symptoms. Of those patients who not develop detectable IgG antibodies, all have detectable virus-neutralizing antibodies, suggesting immunity. Our results showing that not all COVID-19 patients develop detectable IgG using two validated commercial clinical methods, even over time, are vital for the interpretation of COVID-19 seroprevalence surveys and for estimating the true infection prevalence in populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swedish State Support for Clinical Research (ALFGBG-717531 (MG) and 679621 (SL)) and by SciLifeLab/KAW national COVID-19 research program (V-2020-0250 (MG) and 2020-0182 (DA, MB, AL)). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Swedish Ethical Review Authority (Registration number 2020-01771) and patients were included after written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are fully available without restriction https://doi.org/10.5281/zenodo.3934337